FDA panel backs Pfizer's low-dose Covid-19 vaccine for kids

A Food and Drug Administration advisory panel voted unanimously, with one abstention, that the vaccine's benefits in preventing Covid-19 in that age group outweigh any potential risks. That includes questions about a heart-related side effect that's been very rare in teens and young adults despite their use of a much higher vaccine dose.